×

Immunotherapeutics

PowderMed Ltd.

http://www.powdermed.com

About PowderMed Ltd - www.powdermed.com PowderMed Ltd, a leader in the development of therapeutic DNA vaccines, based in Oxford, UK, was launched in May 2004 as a management spin out of the PowderJect therapeutic DNA vaccine programmes, previously owned by Chiron Vaccines. The Company has the rights to the PowderJect® DNA particle mediated epidermal delivery (PMED) technology which it plans to use, in the first instance, in the development of therapeutic vaccines in the areas of chronic viral diseases and cancer. PowderMed has five preclinical lead programmes targeting genital herpes, hepatitis B, genital warts, HIV/AIDS (partnered with GSK) and lung cancer (partnered with Ludwig Institute for Cancer Research).

  • 12/8/2013
  • 5
  • 0

Cel Sci Corp

http://www.cel-sci.com

CEL-SCI Corporation is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted, it is the cancer immunotherapy that both kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. Multikine is a type of immunotherapy in that it is a immunotherapy, incorporating both active and passive immune activity. (Source: 10-K)

  • 12/8/2013
  • 5
  • 0

Antigenics , Inc.

http://www.antigenics.com

Antigenics Inc. is a biotechnology company focused on developing technologies and product candidates to treat cancers and infectious diseases, primarily based on immunological approaches. The Company’s principal product candidate is Oncophage (vitespen), a patient-specific therapeutic cancer vaccine candidate that has been tested, or is being tested, in several cancer indications. The product candidate portfolio also includes QS-21 Stimulon adjuvant (QS-21), an investigational adjuvant used in vaccines under development for a variety of diseases, including but not limited to, hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer’s disease, malaria and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes, and Aroplatin, a liposomal chemotherapeutic for the treatment of solid tumors and B-cell lymphomas. (Source: 10-K)

  • 12/8/2013
  • 8
  • 0

ID Biomedical Corporation

http://www.idbiomed.com

ID Biomedical is an integrated biotechnology company dedicated to the development of innovative vaccine products. It operates in research, development, manufacturing, sales and marketing from its facilities in Canadaand in the United States. ID Biomedical is dedicated to becoming a premier vaccine company with significant marketed products worldwide and an extensive pipeline in both clinical and preclinical development. ID Biomedical has a leading position in the Canadian influenza market. It received a ten-year mandate from the Government of Canada in 2001 to assure a state of readiness in the case of an influenza pandemic and provide influenza vaccine for all Canadians in such an event. It also currently supplies approximately 75% of the Canadian government's influenza vaccine purchases.

  • 12/8/2013
  • 6
  • 0

Note

Not found any data